A study to evaluate the safety and efficacy of Eculizumab in patients with relapsing NMO

Brief Description Of Study

The primary purpose of this study is to assess how effective eculizumab treatment is compared with placebo in relapsing NMO patients based on the time to first relapse and relapse risk reduction. Eligible patients will be randomized 2:1 to one of two treatment arms: 1) eculizumab infusion or 2) placebo infusion. In this "time-to-event" trial, the trial duration for an individual patient will vary depending on when a patient enters the trial and on the patient’s outcome. The course of the trial for an individual patient will consist of: Screening Period, Study Period, and Safety Follow-up Period. Patients may be provided with the opportunity to participate in an extension trial to receive eculizumab.

Clinical Study Identifier: TX1053

Additional Information About The Study

Eculizumab/ Placebo will be administered as follows: The Induction Phase: Placebo or Eculizumab infusion weekly for 5 weeks Maintenance Phase: Placebo or Eculizumab infusion every 2 weeks from the time of the last dose of the induction phase.

Contact research investigator to learn more about this study by filling out the form below.


To: Research Study Investigator
Subject: I am interested in participating in your Research Study
Dear Investigator,
I'm interested in learning more about and participating in your research study named: A study to evaluate the safety and efficacy of Eculizumab in patients with relapsing NMO
I am hoping to hear back from you and discuss details of the study

By clicking "Contact Research Team", your contact information will be sent directly to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.